Celase® Distribution Agreement
Worthington Biochemical Corporation Announces Expansion of GMP Compliant Enzyme Offering via Strategic Agreement with Cytori Therapeutics
Worthington Biochemical Corporation Signs a Non-exclusive, 3 Year Distribution Agreement for Cytori Celase® GMP Enzymes
LAKEWOOD, NJ (November 30, 2015) – Worthington announced today distribution rights to the Celase® GMP compliant enzyme from Cytori Therapeutics, San Diego, CA. The new Celase® GMP product offering allows Worthington customers focused on cell isolation studies to facilitate a smooth transition from bench and animal research to downstream clinical applications.
Celase® GMP is a proprietary enzyme containing a unique blend of collagenase, neutral protease and buffer salts that are produced using avian and mammalian tissue-free raw materials, aseptically processed, sterile filtered and highly purified under GMP guidelines. A single, sterile, ready to use enzyme containing both collagenase and a neutral protease is ideal for a wide range of adipose stem cell, biomedical and bioprocessing applications.
“We are excited to offer Cytori’s Celase® GMP product to Worthington’s Collagenase and STEMxyme® portfolio for biomedical research and related bioprocessing applications. It was very important for us to find an enzyme that meets our stringent requirements for high quality and reproducible performance,” said Von Worthington, President and CEO at Worthington Biochemical Corporation. “This new Celase® GMP product offering will be marketed through our catalog, direct sales force, distributor network, e-commerce website and upcoming scientific meetings.”
Cytori Therapeutics’ extensive product development expertise yields a best-in-class enzyme formulation providing researchers with superior and unparalleled convenience in their lab, clarity in their approach, and confidence in their results.
“We are very excited and pleased to initiate a partnership for Celase® GMP with a respected enzyme manufactured like Worthington which has decades of experience successfully serving the biomedical research and technology field,” said Russ Havranek, Director of Marketing at Cytori Therapeutics.
About Worthington Biochemical Corporation
Founded in 1947, Worthington Biochemical Corporation is an industry leader in the development and production of high quality purified enzymes, proteins, nucleic acids and cell isolation kits for life science research, diagnostics and biotechnology applications. An ISO9001 Certified, primary manufacturer Worthington meets enzyme requirements from research to scale-up bulk bioprocessing and OEM applications. Worthington Biochemical Corporation is a privately held company, headquartered in Lakewood, NJ and has worldwide distribution through a network of exclusive distributors.
About Cytori Therapeutics
Cytori Therapeutics is a late stage cell therapy company developing autologous cell therapies from adipose tissue to treat a variety of medical conditions. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy™ acts principally by improving blood flow, modulating the immune system, and facilitating wound repair. As a result, Cytori Cell Therapy™ may provide benefits across multiple disease states and can be made available to the physician and patient at the point-of-care through Cytori’s proprietary technologies and products. For more information visit www.cytori.com
